1
|
Aguado JM, Navarro D, Montoto C, Yébenes M, de Castro-Orós I. Incidence of refractory CMV infection with or without antiviral resistance in Spain: A systematic literature review. Transplant Rev (Orlando) 2024; 38:100804. [PMID: 37949797 DOI: 10.1016/j.trre.2023.100804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 10/26/2023] [Accepted: 10/30/2023] [Indexed: 11/12/2023]
Abstract
INTRODUCTION Solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT) recipients are susceptible to cytomegalovirus (CMV) infection. The incidence of refractoriness to antivirals, with or without resistance, is unclear. The purpose of this review was to describe the epidemiology of refractory CMV infection in Spain to understand the current unmet needs. METHODS PubMed, EMBASE, Cochrane and MEDES were searched systematically for relevant articles. We included randomized controlled trials and observational studies published during the period from January 1990 to June 2021. RESULTS From 212 screened records, we selected 19 papers including 1973 transplant recipients. Refractory infection ranged from 3 to 10% in studies with SOT recipients. The incidence of CMV resistance ranged from 1% to 36% in these patients. The incidence of CMV refractory infection in HSCT recipients ranged from 11 to 50%, while values for resistant infection ranged from 0% to 21%. CONCLUSION The wide range of definitions and values observed does not allow us to establish the true incidence of refractory CMV infection with or without resistances in SOT and HSCT patients in Spain. This review highlights the gap between clinical practice and clinical trials' definitions which needed to be updated to be easier followed in current clinical practice.
Collapse
Affiliation(s)
- J M Aguado
- Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre", Universidad Complutense, Calle del Dr. Tolosa Latour, s/n, 28041 Madrid, Spain
| | - D Navarro
- Microbiology Service, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain; Department of Microbiology, School of Medicine, University of Valencia, Av. De Blasco Ibáñez, 17, 46010, Valencia, Spain
| | - C Montoto
- Takeda Pharmaceutical Company Limited, P° Castellana 95, 22(nd) floor, 28046 Madrid, Spain
| | - M Yébenes
- Pharmacoeconomics & Outcomes Research Iberia (PORIB), P° Joaquin Rodrigo, 4 I, 28224 Pozuelo de Alarcón, Madrid, Spain.
| | - I de Castro-Orós
- Takeda Pharmaceutical Company Limited, P° Castellana 95, 22(nd) floor, 28046 Madrid, Spain
| |
Collapse
|
2
|
Joven B, Hernández Sánchez R, Pérez-Pampín E, Aragón Díez Á, Almodóvar R, Martínez-Ferrer Á, Belzunegui J, Rubio E, Díaz-Cerezo S, Moyano S, Gómez-Barrera M, Yébenes M, Núñez M. Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study. Rheumatol Ther 2023; 10:1319-1333. [PMID: 37481752 PMCID: PMC10468471 DOI: 10.1007/s40744-023-00584-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 06/30/2023] [Indexed: 07/25/2023] Open
Abstract
INTRODUCTION Ixekizumab (IXE) is an IgG4-type monoclonal antibody targeting IL-17A indicated alone or in combination with methotrexate, for the treatment of active psoriatic arthritis (PsA) in adult patients with insufficient response or with intolerance to one or more disease-modifying anti-rheumatic drug (DMARD) therapy. The PRO-STIP study aimed to describe persistence, patient characteristics, treatment patterns, and effectiveness in patients with PsA receiving IXE in a real-world clinical setting in Spain. METHODS This was an observational, multicentric, retrospective, longitudinal study in adult PsA patients who started IXE between January 2019 and December 2020, with at least 24 weeks of follow-up. A descriptive analysis of patient characteristics and treatment patterns was performed. The primary objective, treatment persistence, was estimated by Kaplan-Meier survival curve. Effectiveness was evaluated by Disease Activity in Psoriatic Arthritis (DAPSA) scores at baseline and at 12 and 24 weeks. RESULTS Eighty-nine patients met the selection criteria (55.1% women and mean age 51.5 years). The median time from PsA diagnosis to starting IXE was 7.7 years (IQR 3.4-14.6). Prior to IXE, 95.5% patients had been treated with at least one biologic or targeted synthetic DMARD (b/tsDMARD). The observed persistence rates were 95.5%, 84.3% and 68.5% at 24, 48, and 104 weeks, respectively. The median persistence was not reached in the study period (mean persistence, 86.9 [95% CI 80.6-93.2] weeks). Twenty-eight (31.5%) patients discontinued IXE, 19 patients (21.3%) due to loss of effectiveness and two patients (2.2%) due to adverse events. In patients receiving treatment and with available effectiveness assessment (n = 24), DAPSA decreased significantly from baseline 23.7 (95% CI 19.5-27.9) to 14.8 (95% CI 10.5-19.2) at 12 weeks (p = 0.005) and 14.3 (95% CI 11.1-17.4) at 24 weeks (p = 0.004). CONCLUSIONS PsA patients treated with IXE in a real-world setting show high treatment persistence through 104 weeks and improvements in disease activity after treatment initiation. This suggests that IXE could be an effective treatment for patients with PsA. RETROSPECTIVELY REGISTERED Date of registration: 25th May 2021.
Collapse
Affiliation(s)
- Beatriz Joven
- Hospital Universitario, 12 de Octubre, Madrid, Spain
| | | | - Eva Pérez-Pampín
- Hospital Clínico Universitario Santiago, Santiago de Compostela, Spain
| | | | | | | | | | - Esteban Rubio
- Hospital Universitario Virgen del Rocío, Seville, Spain
| | | | | | - Manuel Gómez-Barrera
- Pharmacoeconomics and Outcomes Research Iberia (PORIB), Pozuelo de Alarcón, Madrid, Spain
| | - María Yébenes
- Pharmacoeconomics and Outcomes Research Iberia (PORIB), Pozuelo de Alarcón, Madrid, Spain
| | | |
Collapse
|
3
|
Moreno-Arrones OM, Ardebol SB, Martinez FM, Pastor GP, Navarro IT, Ortí MB, Deza-Vargas LG, Salas VR, Masferrer E, Feal C, Merino LT, Toll A, Yébenes M, Mejías SG, Jaka A, Pulido CF, Florez A, Hernández NH, de-Misa RF, Buceta LR, Sanmartin O. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study. Actas Dermosifiliogr 2023:S0001-7310(23)00482-9. [PMID: 37302483 DOI: 10.1016/j.ad.2023.06.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Accepted: 04/18/2023] [Indexed: 06/13/2023] Open
Abstract
BACKGROUND Basal cell carcinoma (BCC) is the most prevalent cancer. A minority of BCCs have an aggressive behaviour (laBCC) and may require hedgehog pathway inhibitors such as sonidegib as its treatment. OBJECTIVE To describe the use of sonidegib in a large number of patients and provide more data on its real-life efficacy and safety profile. METHODS We conducted a retrospective and multicentric study that included patients treated with sonidegib. Epidemiological, effectiveness and safety data were collected. RESULTS A total of 82 patients with a mean age of 73.9 years were included. Ten patients had Gorlin syndrome. Median treatment duration was 6 months. Median follow-up duration was 34.2 months. Globally, 81.7% of the patients showed clinical improvement (52.4% partial response and 29.3% complete response), 12.2% clinical stability and 6.1% disease progression. There was no statistically significant difference in clinical improvement between the 24 h and 48 h sonidegib posology. After 6 months of treatment, 48.8% of the patients discontinued sonidegib. Prior vismodegib treatment and recurrent primary BCC were associated with a poorer response to sonidegib. At 6 months of treatment, 68.3% of the patients experienced at least one adverse effect. CONCLUSION Sonidegib shows good effectiveness and acceptable safety profile in usual clinical practice.
Collapse
Affiliation(s)
- O M Moreno-Arrones
- Dermatology Department, Ramon y Cajal University Hospital, University of Alcala, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
| | - S Béa Ardebol
- Dermatology Department, Ramon y Cajal University Hospital, University of Alcala, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
| | - F Mayo Martinez
- Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
| | - G Pérez Pastor
- Department of Dermatology, Consorci Hospital General Universitari de Valencia, Valencia, Spain
| | - I Torres Navarro
- Department of Dermatology; Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - M Bonfill Ortí
- Department of Dermatology; Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - L G Deza-Vargas
- Department of Dermatology; Hospital del Mar, Barcelona, Spain
| | - V Ruiz Salas
- Department of Dermatology Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - E Masferrer
- Dermatology Department, Hospital Universitari Mútua de Terrassa, Barcelona, Spain
| | - C Feal
- Dermatology Department, Hospital de Pontevedra, Galicia, Spain
| | - L Turrión Merino
- Dermatology Department, Hospital Puerta de Hierro, Madrid, Spain
| | - A Toll
- Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain
| | - M Yébenes
- Department of Dermatology, Consorci Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain
| | - S Galiano Mejías
- Department of Dermatology, Hospital Infanta Leonor, Madrid, España
| | - A Jaka
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - C Ferrandiz Pulido
- Department of Dermatology, Hospital Universitari Vall d'Hebron. Facultad de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - A Florez
- Dermatology Department, Hospital de Pontevedra, Galicia, Spain
| | - N Hernández Hernández
- Department of Dermatology. Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
| | - R Fernández de-Misa
- Department of Dermatology. Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
| | - L Rios Buceta
- Dermatology Department, Ramon y Cajal University Hospital, University of Alcala, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
| | - O Sanmartin
- Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
| |
Collapse
|
4
|
Moreno-Arrones OM, Béa-Ardebol S, Mayo-Martinez F, Pérez-Pastor G, Torres-Navarro I, Bonfill-Ortí M, Deza-Vargas LG, Ruiz-Salas V, Masferrer E, Feal C, Turrión-Merino L, Toll A, Yébenes M, Galiano-Mejías S, Jaka A, Ferrandiz-Pulido C, Florez A, Hernández-Hernández N, Fernández-de-Misa R, Rios-Buceta L, Sanmartin O. Sonidegib as a locally advanced basal cell carcinoma therapy in real-life clinical setting: a national multicentre study. Actas Dermosifiliogr 2023:S0001-7310(23)00318-6. [PMID: 37088285 DOI: 10.1016/j.ad.2023.04.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Revised: 04/16/2023] [Accepted: 04/18/2023] [Indexed: 04/25/2023] Open
Abstract
BACKGROUND Basal cell carcinoma (BCC) is the most prevalent cancer. A minority of BCCs have an aggressive behaviour (laBCC) and may require hedgehog pathway inhibitors such as sonidegib as its treatment. OBJECTIVE To describe the use of sonidegib in a large number of patients and provide more data on its real-life efficacy and safety profile. METHODS We conducted a retrospective and multicentric study that included patients treated with sonidegib. Epidemiological, effectiveness and safety data were collected. RESULTS A total of 82 patients with a mean age of 73.9 years were included. Ten patients had Gorlin syndrome. Median treatment duration was 6 months. Median follow-up duration was 34.2 months. Globally, 81.7% of the patients showed clinical improvement (52.4% partial response and 29.3% complete response), 12.2% clinical stability and 6.1% disease progression. There was no statistically significant difference in clinical improvement between the 24h and 48h sonidegib posology. After 6 months of treatment, 48.8% of the patients discontinued sonidegib. Prior vismodegib treatment and recurrent primary BCC were associated with a poorer response to sonidegib. At 6 months of treatment, 68.3% of the patients experienced at least one adverse effect. CONCLUSION Sonidegib shows good effectiveness and acceptable safety profile in usual clinical practice.
Collapse
Affiliation(s)
- O M Moreno-Arrones
- Dermatology Department, Ramon y Cajal University Hospital, University of Alcala, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
| | - S Béa-Ardebol
- Dermatology Department, Ramon y Cajal University Hospital, University of Alcala, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
| | - F Mayo-Martinez
- Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
| | - G Pérez-Pastor
- Department of Dermatology, Consorci Hospital General Universitari de Valencia, Valencia, Spain
| | - I Torres-Navarro
- Department of Dermatology; Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - M Bonfill-Ortí
- Department of Dermatology; Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - L G Deza-Vargas
- Department of Dermatology; Hospital del Mar, Barcelona, Spain
| | - V Ruiz-Salas
- Department of Dermatology Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - E Masferrer
- Dermatology Department, Hospital Universitari Mútua de Terrassa, Barcelona, Spain
| | - C Feal
- Dermatology Department, Hospital de Pontevedra, Galicia, Spain
| | - L Turrión-Merino
- Dermatology Department, Hospital Puerta de Hierro, Madrid, Spain
| | - A Toll
- Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain
| | - M Yébenes
- Department of Dermatology, Consorci Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain
| | - S Galiano-Mejías
- Department of Dermatology, Hospital Infanta Leonor, Madrid, España
| | - A Jaka
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - C Ferrandiz-Pulido
- Department of Dermatology, Hospital Universitari Vall d'Hebron. Facultad de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - A Florez
- Dermatology Department, Hospital de Pontevedra, Galicia, Spain
| | - N Hernández-Hernández
- Department of Dermatology. Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
| | - R Fernández-de-Misa
- Department of Dermatology. Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
| | - L Rios-Buceta
- Dermatology Department, Ramon y Cajal University Hospital, University of Alcala, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
| | - O Sanmartin
- Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
| |
Collapse
|
5
|
Castañeda S, Vicente E, Llamas Velasco M, Sanchez Perez J, Pardo J, Cabeza-Martínez R, Miranda-Fontes M, Márquez J, Calvo J, Armesto S, Belinchón I, Gómez A, Miranda MD, Martinez Pardo S, Merino-Meléndez L, Casado MA, Yébenes M, Casado A. OP0262-HPR COST OF ILLNESS IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS. COEPSO STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Psoriasis (Ps) and psoriatic arthritis (PsA) have a major impact on patients’ health-related quality of life. Cost of illness of patients with Ps, PsA and both diseases (PsA+Ps) is an important subject as they are associated with a substantial economic impact, with implications from a health management perspective.Objectives:To describe the economic burden of direct non-healthcare and indirect resources of patients with Ps, PsA and PsA+Ps in Spain.Methods:COEPSO (“Evaluation of Costs in patients with Psoriatic Disease”) was an observational, retrospective, cross-sectional study performed in 22 Spanish centers (17 Dermatology and 14 Rheumatology Services), from February 2017 to February 2018, including moderate to severe Ps and PsA patients (with or without Ps), naive to biologics. Direct non-healthcare (social services, home care, physical adaptations, private health and non-health professionals, non-reimbursed and non-pharmaceutical therapies), indirect (loss of productivity) and total costs (direct non-healthcare and indirect costs) related to the disease during the previous year to the study were obtained. Unitary costs (€, 2018) were calculated: out-of-pocket costs were specified directly by patients and loss of productivity costs by means of average salaries based on occupation specified by patients. The information was collected through a case report form filled out by the investigators and a telephone survey administered to the patients.Results:A total of 318 patients were included (196 Ps; 43 PsA and 79 PsA+Ps), mean age 48.7 years and 51.3% males. Metabolic syndrome was the most frequent comorbidity in all groups. The average annual total cost per patient was 1,042.71€ (SD 3,817.55), 1,137.84€ (SD 3,070.39) and 1,830.26€ (SD 5,835.81) for Ps, PsA and PsA+Ps, respectively. The average annual direct non-healthcare cost per patient was 749.57€ (SD 2,393.77), 750.50€ (SD 1,641.82) and 1,247.56€ (SD 4,467.19) for Ps, PsA and PsA+Ps, respectively. The average annual indirect cost per patient was 293.14€ (SD 2,855.27), 387.35€ (SD 2,409.63) and 582.71€ (SD 3,842.12) for Ps, PsA and PsA+Ps, respectively.Patients with combined PsA+Ps had higher annual total cost (direct non-healthcare and indirect costs) than patients with only one of these manifestations separately (75.5% and 60.9% above patients with Ps and PsA, respectively). Total costs in patients with Ps and PsA were similar. Direct non-healthcare costs represent between 66.0% (patients with PsA) to 71.9% (patients with Ps) of total cost. Indirect costs represent between 28.1% (patients with Ps) to 34.0% (patients with PsA) of total cost.Conclusion:PsA and Ps have proved to be diseases with a high economic burden, and the total costs were mainly driven by direct non-healthcare costs. Moreover, although annual total costs in patients with PsA were similar to those of Ps patients, the combination of both manifestations yielded the highest costs suggesting the importance of the increased disease load.Disclosure of Interests:Santos Castañeda: None declared, Esther Vicente Speakers bureau: BMS, Roche., Mar Llamas Velasco: None declared, Javier Sanchez Perez: None declared, José Pardo: None declared, Rita Cabeza-Martínez: None declared, Mercedes Miranda-Fontes: None declared, Juan Márquez: None declared, Jaime Calvo Grant/research support from: Lilly, UCB, Consultant of: Abbvie, Jansen, Celgene, susana armesto: None declared, Isabel Belinchón: None declared, Alejandro Gómez: None declared, María Dolores Miranda: None declared, Silvia Martinez Pardo: None declared, Leticia Merino-Meléndez: None declared, Miguel Angel Casado Consultant of: UCB Pharma, María Yébenes: None declared, Araceli Casado: None declared
Collapse
|
6
|
Berlana D, Almendral MA, Abad MR, Fernández A, Torralba A, Cervera‐Peris M, Piñeiro G, Romero‐Jiménez R, Vázquez A, Ramírez E, Yébenes M, Muñoz Á. Cost, Time, and Error Assessment During Preparation of Parenteral Nutrition: Multichamber Bags Versus Hospital‐Compounded Bags. JPEN J Parenter Enteral Nutr 2018; 43:557-565. [DOI: 10.1002/jpen.1436] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2018] [Revised: 07/02/2018] [Accepted: 07/17/2018] [Indexed: 12/12/2022]
Affiliation(s)
- David Berlana
- Vall d´Hebron Barcelona Hospital Campus Barcelona Spain
| | | | | | | | | | | | | | | | - Amparo Vázquez
- La Fe University and Politechnic Hospital Valencia Spain
| | | | - María Yébenes
- Pharmacoeconomics & Outcomes‐Research‐Iberia Pozuelo de Alarcón Spain
| | - Álvaro Muñoz
- Pharmacoeconomics & Outcomes‐Research‐Iberia Pozuelo de Alarcón Spain
| |
Collapse
|
7
|
Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, Gutiérrez ML, Suárez E, Rubio MG, López J, Castillo P, Rodríguez M, Zozaya JM, Simón MA, Morano LE, Calleja JL, Yébenes M, Esteban R. Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS One 2018; 13:e0199926. [PMID: 29940039 PMCID: PMC6016912 DOI: 10.1371/journal.pone.0199926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0184550.].
Collapse
|
8
|
Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, Gutiérrez ML, Suárez E, Gómez Rubio M, López J, Castillo P, Rodríguez M, Zozaya JM, Simón MA, Morano LE, Calleja JL, Yébenes M, Esteban R. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS One 2017; 12:e0184550. [PMID: 28898281 PMCID: PMC5595327 DOI: 10.1371/journal.pone.0184550] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2017] [Accepted: 08/10/2017] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg negative, antiHBc positive) is uncommon, but potentially fatal. The role of HBV prophylaxis in this setting is uncertain. The aim of this study was to compare the efficacy of tenofovir disoproxil fumarate (TDF) prophylaxis versus close monitoring in antiHBc-positive, HBsAg-negative patients under treatment with rituximab (RTX)-based regimens for hematologic malignancy. METHODS PREBLIN is a phase IV, randomized, prospective, open-label, multicenter, parallel-group trial conducted in 17 hospitals throughout Spain. Anti-HBc-positive, HBsAg-negative patients with undetectable HBV DNA were randomized to receive TDF 300 mg once daily (Group I) or observation (Group II). The primary endpoint was the percentage of patients showing HBV reactivation during 18 months following initiation of RTX treatment. Patients with detectable HBV DNA (Group III) received the same dose of TDF and were analyzed together with Group I to investigate TDF safety. RESULTS Sixty-one patients were enrolled in the study, 33 in the TDF treatment group and 28 in the observation group. By ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091). None of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample. TDF was generally well tolerated and there were no severe treatment-related adverse events. CONCLUSION In patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.
Collapse
Affiliation(s)
- María Buti
- Liver Unit, Hospital Vall Hebron and CIBEREHD del Instituto Carlos III, Barcelona, Spain
| | - María L. Manzano
- Department of Hepatology, Hospital Doce de Octubre, Madrid, Spain
| | - Rosa M. Morillas
- Department of Hepatology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
| | | | - Leticia Martín
- Department of Hepatology, Hospital de Donostia, San Sebastián, Spain
| | - Martín Prieto
- Department of Hepatology, Hospital Universitario i Politécnico La Fe, Valencia, Spain
| | | | - Emilio Suárez
- Department of Hepatology, Hospital Nuestra Señora de Valme, Seville, Spain
| | | | - Javier López
- Department of Hematology, Hospital Ramón y Cajal, Madrid, Spain
| | - Pilar Castillo
- Department of Hepatology, Hospital La Paz, Madrid, Spain
| | - Manuel Rodríguez
- Department of Hepatology, Hospital Central de Asturias, Oviedo, Spain
| | - José M. Zozaya
- Department of Gastroenterology, Hospital de Navarra, Pamplona, Spain
| | - Miguel A. Simón
- Department of Hepatology, Hospital Clínico Lozano Blesa, Zaragoza, Spain
| | - Luis E. Morano
- Department of Infectious Diseases, Hospital do Meixoeiro, Vigo, Spain
| | - José L. Calleja
- Department of Gastroenterology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain
| | - María Yébenes
- Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain
| | - Rafael Esteban
- Liver Unit, Hospital Vall Hebron and CIBEREHD del Instituto Carlos III, Barcelona, Spain
| |
Collapse
|
9
|
Gil S, Yébenes M, Luelmo J, Alsina M, Sabés M. A comparative study of the effectiveness of cisplatin and 5-fluorouracil on cutaneous squamous human carcinoma cell line: Potential chemotherapy alternative to surgery. Dermatol Ther 2016; 29:341-344. [PMID: 27292650 DOI: 10.1111/dth.12373] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Surgery as treatment for local invasive cutaneous squamous cell carcinoma (cSCC) is not always feasible due to the age and/or the health status of patients. Thus, the investigation of new strategies to improve the quality of life of them is required. The aim of this work is to investigate two chemotherapy agents individually on cSCC cells with the purpose to provide a better understanding of the effectiveness underlying each one. The cisplatin effectiveness is compared at different times with that observed for the 5-fluorouracil treatment. The effectiveness of both was assessed by using flow cytometry to determine the survival cell ratio, and QBlue test to study the cell recovery ability after treatments. A significant increase in the number of apoptotic cells, especially 48 hours after treatments, has been detected. Despite this, cisplatin arises as the most promising agent for the treatment of local invasive cutaneous squamous cell carcinoma due to the fact that a lower concentration and time are required to observe a higher effectiveness on cells with respect to the 5-fluorouracil. An optimal cisplatin-based chemotherapy might provide a better outcome for patients affected by a local invasive cSCC rather than surgery.
Collapse
Affiliation(s)
- S Gil
- Dermatology Department, Hospital Parc Taulí, Sabadell (Barcelona), Spain.
| | - M Yébenes
- Dermatology Department, Hospital Parc Taulí, Sabadell (Barcelona), Spain
| | - J Luelmo
- Dermatology Department, Hospital Parc Taulí, Sabadell (Barcelona), Spain
| | - M Alsina
- Dermatology Department, Hospital Clínic de Barcelona, Barcelona, Spain
| | - M Sabés
- Department of Biophysics, Faculty of Medicine, Universitat Autònoma de Barcelona, Bellaterra (Barcelona), Spain
| |
Collapse
|
10
|
Requena T, Ais A, Yébenes M, Casado MA, Rueda M. Persistence with oral antiviral therapy in previously untreated patients with chronic hepatitis B in Spain: the EUPTHEA study. Eur J Hosp Pharm 2014. [DOI: 10.1136/ejhpharm-2014-000452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
11
|
Pujol R, Puig L, Daudén E, Sánchez-Carazo J, Toribio J, Vanaclocha F, Yébenes M, Sabater E, Casado M, Caloto M, Aragón B. Mental Health Self-Assessment in Patients With Moderate to Severe Psoriasis: An Observational, Multicenter Study of 1164 Patients in Spain (The VACAP Study). Actas Dermo-Sifiliográficas 2013; 104:897-903. [DOI: 10.1016/j.ad.2013.04.014] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2012] [Revised: 03/21/2013] [Accepted: 04/14/2013] [Indexed: 11/29/2022] Open
|
12
|
Pujol R, Puig L, Daudén E, Sánchez-Carazo J, Toribio J, Vanaclocha F, Yébenes M, Sabater E, Casado M, Caloto M, Aragón B. Mental Health Self-Assessment in Patients With Moderate to Severe Psoriasis: An Observational, Multicenter Study of 1164 Patients in Spain (The VACAP Study). Actas Dermo-Sifiliográficas (English Edition) 2013. [DOI: 10.1016/j.adengl.2013.04.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
13
|
Daudén E, Pujol R, Sánchez-Carazo J, Toribio J, Vanaclocha F, Puig L, Yébenes M, Sabater E, Casado M, Caloto M, Aragón B. Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study. Actas Dermo-Sifiliográficas (English Edition) 2013. [DOI: 10.1016/j.adengl.2013.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
14
|
Mar J, Álvarez-Sabín J, Oliva J, Becerra V, Casado M, Yébenes M, González-Rojas N, Arenillas J, Martínez-Zabaleta M, Rebollo M, Lago A, Segura T, Castillo J, Gállego J, Jiménez-Martínez C, López-Gastón J, Moniche F, Casado-Naranjo I, López-Fernández J, González-Rodríguez C, Escribano B, Masjuan J. Los costes del ictus en España según su etiología. El protocolo del estudio CONOCES. Neurologia 2013; 28:332-9. [DOI: 10.1016/j.nrl.2012.07.004] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2012] [Revised: 07/10/2012] [Accepted: 07/13/2012] [Indexed: 11/30/2022] Open
|
15
|
Martín-Ezquerra G, Salgado R, Toll A, Gilaberte M, Baró T, Alameda Quitllet F, Yébenes M, Solé F, Garcia-Muret M, Espinet B, Pujol R. Multiple genetic copy number alterations in oral squamous cell carcinoma: study of MYC
, TP53
, CCDN1, EGFR
and ERBB2
status in primary and metastatic tumours. Br J Dermatol 2010; 163:1028-35. [DOI: 10.1111/j.1365-2133.2010.09947.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Toll A, Salgado R, Yébenes M, Martín-Ezquerra G, Gilaberte M, Baró T, Solé F, Alameda F, Espinet B, Pujol R. MYCgene numerical aberrations in actinic keratosis and cutaneous squamous cell carcinoma. Br J Dermatol 2009; 161:1112-8. [DOI: 10.1111/j.1365-2133.2009.09351.x] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
17
|
Yébenes M, Toll A, Giménez-Arnau A, Ferran M, Parera E, Fraga J, Barranco C, Pujol RM. Pseudotumoral primary syphilis on the tongue in an HIV positive patient. Clin Exp Dermatol 2008; 33:509-11. [DOI: 10.1111/j.1365-2230.2008.02690.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
18
|
Yébenes M, Toll A, Vélez M, Barranco C, Alonso-López NA, Gonzalez-Sarmiento R, Bellosillo B, Pujol RM. Linear unilateral hamartomatous basal cell naevus with glandular and follicular differentiation. Clin Exp Dermatol 2008; 33:429-32. [PMID: 18312461 DOI: 10.1111/j.1365-2230.2007.02663.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Mosaicisms are characterized by genetic or functional differences between > or = 2 cell lines in one person, derived from a single zygote. Of the various clinical patterns of cutaneous mosaicism, linear lesions following Blaschko's lines are probably the most commonly encountered, Several cases of multiple basal cell carcinomas or basaloid hamartomatous lesions distributed in a segmentary distribution and following Blaschko's lines have been described. The various terms of 'linear unilateral basal cell naevus with comedones', 'linear unilateral basaloid follicular hamartoma', 'linear unilateral basal cell naevus', and 'basal-cell and linear unilateral adnexal hamartoma' have been used to define this apparently heterogeneous group of disorders. We report a 66-year-old woman with a linear unilateral lesion that appeared during puberty and that histologically showed an adnexal hamartomatous lesion with multiple superficial and nodular basal cell carcinomas. Focal areas of glandular and follicular differentiation were also noted. Molecular studies from these lesions ruled out loss of heterozygosity or mutations in patched gene.
Collapse
Affiliation(s)
- M Yébenes
- Department of Dermatology, Hospital del Mar IMAS, Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Yébenes M, Cruz I, Cañavate C, Gilaberte M, Baena V, Pujol RM. Nodular lymphangitic subcutaneous dissemination after intralesional antimonial treatment for localized cutaneous leishmaniasis. Clin Exp Dermatol 2008; 33:142-4. [DOI: 10.1111/j.1365-2230.2007.02575.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
Fernández-Casado A, Martin-Ezquerra G, Yébenes M, Plana F, Elvira-Betanzos JJ, Herrero-González JE, Mariñoso ML, Pujol RM. Progressive supravenous granulomatous nodular eruption in a human immunodeficiency virus-positive intravenous drug user treated with highly active antiretroviral therapy. Br J Dermatol 2007; 158:145-9. [PMID: 17941945 DOI: 10.1111/j.1365-2133.2007.08238.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
We describe a 41-year-old human immunodeficiency virus-infected woman with a previous history of intravenous drug abuse, who developed multiple linear nodules following the superficial veins on both arms. Histopathological examination disclosed a dermal histiocytic inflammatory reaction with sarcoid-like granuloma formation occasionally showing an intracytoplasmic refractile material in the histiocytic cells. Nodular lesions developed progressively after starting on highly active antiretroviral therapy (HAART) which increased her CD4 cell count and suppressed her viral load. The appearance of latent inflammatory or autoimmune disease following HAART is a well-recognized phenomenon. We consider that this peculiar 'progressive supravenous granulomatous nodular eruption' should be included within the spectrum of the so-called immune reconstitution inflammatory syndrome.
Collapse
Affiliation(s)
- A Fernández-Casado
- Department of Dermatology, Hospital del Mar-IMAS, Passeig Marítim 25-29, 08003 Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Romaní J, Yébenes M. [Repair of surgical defects of the nasal pyramid]. Actas Dermosifiliogr 2007; 98:302-11. [PMID: 17555672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/15/2023] Open
Abstract
The nose is an area commonly involved in dermatological surgery. Basal cell and squamous cell carcinoma frequently affect the nasal appendix and its adjacent structures. There is a broad repertoire of surgical techniques for the reconstruction of this area, including direct closure, local and distant flaps, and grafts. Small surgical defects may be repaired by direct closure or second intention healing but local flaps and skin grafts from appropriate donor sites are frequently required after excision of tumors. Flaps have substantial advantages over grafts because they have their own blood supply and their viability does not depend entirely on the vascular bed of the surgical defect. Flaps offer similar skin in terms of color, texture and photoaging. Local flaps are essentially classified in several types: advancement, rotation and transposition. In this review we mention and graphically illustrate the reconstruction procedures from our own experience.
Collapse
Affiliation(s)
- J Romaní
- Servicio de Dermatología, Hospital Parc Taulí, Sabadell, Barcelona.
| | | |
Collapse
|
22
|
|
23
|
Yébenes M, Muñoz C, Sábat M, Palacio L, San Vicente B, Travería FJ, Luelmo J. Multiple furunculoid myiasis on the scalp of a child. Dermatol Online J 2007; 13:13. [PMID: 17498432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/15/2023] Open
Abstract
Cutaneous myiasis is easy to diagnose and treat if clinicians are aware of the condition. Because of widespread travel, physicians may encounter this infestation in patients living in geographical regions where the condition is rare. A child is presented with cutaneous myiasis that presented as furuncle-like nodules on the scalp. The larvae were identified as a stage of the bluebottle-like fly, Dermatobia hominis.
Collapse
Affiliation(s)
- M Yébenes
- Department of Dermatology, Hospital Parc Taulí, Sabadell
| | | | | | | | | | | | | |
Collapse
|
24
|
Yébenes M, Muñoz C, Sábat M, Palacio L, Vicente BS, Travería FJ, Luelmo J. Multiple furunculoid myiasis on the scalp of a child. Dermatol Online J 2007. [DOI: 10.5070/d317z0g570] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
25
|
Romaní J, Yébenes M. Repair of Surgical Defects of the Nasal Pyramid. Actas Dermo-Sifiliográficas (English Edition) 2007. [DOI: 10.1016/s1578-2190(07)70453-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
26
|
Gilaberte M, Delclós J, Yébenes M, Barranco C, Pujol RM. Delayed foreign body granuloma secondary to an abandoned cardiac pacemaker wire. J Eur Acad Dermatol Venereol 2007; 21:107-9. [PMID: 17207180 DOI: 10.1111/j.1468-3083.2006.01797.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|